[go: up one dir, main page]

ES2163034T3 - Composiciones micelares de copolimeros de bloque de polieter, para la objetivizacion de agentes biologicos como diana. - Google Patents

Composiciones micelares de copolimeros de bloque de polieter, para la objetivizacion de agentes biologicos como diana.

Info

Publication number
ES2163034T3
ES2163034T3 ES96925932T ES96925932T ES2163034T3 ES 2163034 T3 ES2163034 T3 ES 2163034T3 ES 96925932 T ES96925932 T ES 96925932T ES 96925932 T ES96925932 T ES 96925932T ES 2163034 T3 ES2163034 T3 ES 2163034T3
Authority
ES
Spain
Prior art keywords
compositions
biological agents
micellary
polyeter
objectivation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96925932T
Other languages
English (en)
Inventor
Alexander V Kabanov
Valery Yu Alakhov
Vladimir P Chekhonin
Elena V Batrakova
Victor A Kabanov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Supratek Pharma Inc
Original Assignee
Supratek Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supratek Pharma Inc filed Critical Supratek Pharma Inc
Application granted granted Critical
Publication of ES2163034T3 publication Critical patent/ES2163034T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Nanotechnology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyethers (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

COMPOSICIONES MICELARES DE COPOLIMEROS POLIETER EN BLOQUE QUE CONTIENEN AGENTES BIOLOGICOS COMO FARMACOS ANTITUMORALES O ANTIBIOTICOS, QUE SE EMPLEAN COMO SISTEMAS DE ADMINISTRACION DE FARMACOS PARA TEJIDOS PARTICULARES MARCADOS. LAS COMPOSICIONES SON UTILES PARA LA ADMINISTRACION DE AGENTES BIOLOGICOS EN EL CEREBRO.
ES96925932T 1995-06-07 1996-06-07 Composiciones micelares de copolimeros de bloque de polieter, para la objetivizacion de agentes biologicos como diana. Expired - Lifetime ES2163034T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/478,979 US6153193A (en) 1993-04-28 1995-06-07 Compositions for targeting biological agents

Publications (1)

Publication Number Publication Date
ES2163034T3 true ES2163034T3 (es) 2002-01-16

Family

ID=23902180

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96925932T Expired - Lifetime ES2163034T3 (es) 1995-06-07 1996-06-07 Composiciones micelares de copolimeros de bloque de polieter, para la objetivizacion de agentes biologicos como diana.

Country Status (11)

Country Link
US (1) US6153193A (es)
EP (1) EP0839026B1 (es)
JP (1) JPH11507028A (es)
AT (1) ATE206041T1 (es)
AU (1) AU6628496A (es)
CA (1) CA2236946A1 (es)
DE (1) DE69615561T2 (es)
DK (1) DK0839026T3 (es)
ES (1) ES2163034T3 (es)
PT (1) PT839026E (es)
WO (1) WO1996040056A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153193A (en) * 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
US6277410B1 (en) 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
US6093391A (en) * 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
US6353055B1 (en) 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
US6221959B1 (en) 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
US5869539A (en) * 1996-04-17 1999-02-09 Board Of Regents, The University Of Texas System Emulsions of perfluoro compounds as solvents for nitric oxide (NO)
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US5948896A (en) * 1997-08-13 1999-09-07 Gem Pharmaceuticals Processes for preparing 13-deoxy anthracycline derivatives
US7030155B2 (en) 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
IL141438A0 (en) * 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
US7256180B2 (en) 2000-04-28 2007-08-14 Supratek Pharma Inc. Compositions and methods for inducing activation of dendritic cells
CA2440935A1 (en) * 2001-03-13 2002-09-19 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
FR2822834B1 (fr) * 2001-04-02 2005-02-25 Flamel Tech Sa Suspension colloidale de nanoparticules a base de copolymeres amphiphile pour la vectorisation de principes actifs et leur mode de preparation
PT1392254E (pt) * 2001-04-20 2007-06-29 Univ British Columbia Sistemas de distribuição micelares de fármacos para fármacos hidrofóbicos.
US20030096748A1 (en) * 2001-06-04 2003-05-22 The Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
GB0120701D0 (en) * 2001-08-24 2001-10-17 Maelor Pharmaceuticals Ltd Pharmaceutical formulations
FR2833268B1 (fr) * 2001-12-12 2005-07-08 Fabre Pierre Dermo Cosmetique Nouvelle association contenant un poloxamer et de l'acide chondroitine sulfurique et/ou une glycoproteine et son utilisation
US7074893B2 (en) * 2002-06-03 2006-07-11 Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
FR2840614B1 (fr) * 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
FR2843117B1 (fr) * 2002-07-30 2004-10-15 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement hydrophobe et leurs applications notamment therapeutiques
EP1393718A1 (en) * 2002-08-29 2004-03-03 OctoPlus Sciences B.V. Colloidal drug carrier system
AU2003294056A1 (en) * 2002-12-04 2004-07-29 Flamel Technologies Polyamino acids functionalized by at least one (oligo)amino acid group and therapeutic uses
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
FR2855521B1 (fr) * 2003-05-28 2005-08-05 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement h ydrophobe et leurs applications notamment therapeutiques.
FR2860516B1 (fr) * 2003-10-03 2006-01-13 Flamel Tech Sa Homopolyaminoacides telecheliques fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques
FR2862536B1 (fr) * 2003-11-21 2007-11-23 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
DK2305221T3 (en) * 2003-12-01 2015-08-24 Kudos Pharm Ltd DNA damage repair inhibitors for the treatment of cancer
FR2873704B1 (fr) * 2004-07-30 2006-12-08 Flamel Technologies Sa Polyaminoacides fonctionnalises par des greffons hydrophobes portant une charge anionique et leurs applications notamment therapeutiques
FR2873703B1 (fr) * 2004-07-30 2006-12-08 Flamel Technologies Sa Polyaminoacides branches, fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques
TWI278615B (en) * 2004-12-29 2007-04-11 Ind Tech Res Inst Nano-micelle carrier using in near infrared image detection and detection method therewith
FR2881140B1 (fr) * 2005-01-27 2007-04-06 Flamel Technologies Sa Copolyhydroxyalkylglutamines fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques
FR2892725B1 (fr) * 2005-10-31 2011-03-04 Flamel Tech Sa Acides polyglutamiques fonctionnalises par des derives de l'histidine et des groupements hydrophobes et leurs applications notamment therapeutiques
FR2915748B1 (fr) 2007-05-03 2012-10-19 Flamel Tech Sa Acides polyglutamiques fonctionnalises par des groupes cationiques et des groupements hydrophobes et leurs applications, notamment therapeutiques
WO2010006192A1 (en) * 2008-07-09 2010-01-14 Board Of Regents Of The University Of Nebraska Functional micelles for hard tissue targeted delivery of chemicals
EP2978428A4 (en) * 2013-03-28 2016-12-28 Bbs Nanotechnology Ltd STABLE NANO COMPOSITION WITH EPIRUBICIN, PROCESS FOR THE PRODUCTION THEREOF, THE USE THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREWITH

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4027013A (en) * 1976-01-22 1977-05-31 William L. Wilson Clottable fibrinogen free factor VIII and albumin product and process
US4188373A (en) * 1976-02-26 1980-02-12 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4865835A (en) * 1982-06-02 1989-09-12 Begent Richard H J Diagnosis and treatment of tumors
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4474752A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4957735A (en) * 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
JPS61103836A (ja) * 1984-10-24 1986-05-22 Green Cross Corp:The フイブロネクチン製剤
US5466445A (en) * 1985-06-18 1995-11-14 Emory University Methods for reducing salmonella in chickens
US5114708A (en) * 1985-06-18 1992-05-19 Emory University Method for stimulating growth in animals
IE59233B1 (en) * 1985-06-18 1994-01-26 Univ Emory Use of biologically active copolymers for the manufacture of a medicament for stimulating the growth of an animal
US5234683A (en) * 1985-06-18 1993-08-10 Emory University Method of stimulating the immune system
US5494660A (en) * 1985-06-18 1996-02-27 Emory University Method for inhibiting microbial binding to surfaces
US5183687A (en) * 1985-06-18 1993-02-02 Emory University Method of treating poultry for coccidiosis
EP0211601A3 (en) * 1985-07-30 1988-01-13 International Minerals And Chemical Corporation Stabilization of growth promoting hormones
US5028599A (en) * 1986-05-15 1991-07-02 Emory University Method of treating mycardial damage
US4997644A (en) * 1986-05-15 1991-03-05 Emory University Method of treating adult respiratory distress syndrome
US5198211A (en) * 1986-05-15 1993-03-30 Emory University Method of treating myocardial damage
US4873083A (en) * 1986-05-15 1989-10-10 Emory University Fibrinolytic composition
US5080894A (en) * 1986-05-15 1992-01-14 Emory University Method and composition for reducing tissue damage
US5064643A (en) * 1986-05-15 1991-11-12 Emory University Method for treating sickle cell disease
US5071649A (en) * 1986-05-15 1991-12-10 Emory University Method of preventing blockage in catheters
US4801452A (en) * 1986-05-15 1989-01-31 Hunter Robert L Fibrinolytic composition
US5240702A (en) * 1986-05-15 1993-08-31 Emory University Method of treating stroke
US5047236A (en) * 1986-05-15 1991-09-10 Emory University Method of treating stroke
US4837014A (en) * 1986-05-15 1989-06-06 Emory University An improved method of treating sickle cell anemia
US5089260A (en) * 1986-05-15 1992-02-18 Emory University Method of treating ischemic tissue
US5152979A (en) * 1986-05-15 1992-10-06 Emory University Method for treating vascular obstructions caused by abnormal cells
US4937070A (en) * 1986-05-15 1990-06-26 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US5078995A (en) * 1986-05-15 1992-01-07 Emory University Fibrionolytic composition
US5182106A (en) * 1986-05-15 1993-01-26 Emory University Method for treating hypothermia
US5032394A (en) * 1986-05-15 1991-07-16 Emory University Method of treating burns
US5648071A (en) * 1986-05-15 1997-07-15 Emory University Method of treating tumors
US5030448A (en) * 1986-05-15 1991-07-09 Emory University Method of delivering drugs to damaged or diseased tissue
US5041288A (en) * 1986-05-15 1991-08-20 Emory University Method of treating tissue damaged by reperfusion injury
US5039520A (en) * 1986-05-15 1991-08-13 Emory University Plasma extender
US5240701A (en) * 1986-05-15 1993-08-31 Emory University Method of performing angioplasty procedures
US4879109A (en) * 1986-05-15 1989-11-07 Emory University Method for treating burns
US5017370A (en) * 1986-05-15 1991-05-21 Emory University Improved method of performing angioplasty procedures
US4897263A (en) * 1986-05-15 1990-01-30 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US5250294A (en) * 1986-05-15 1993-10-05 Emory University Improved perfusion medium for transplantation of organs
US4882168A (en) * 1986-09-05 1989-11-21 American Cyanamid Company Polyesters containing alkylene oxide blocks as drug delivery systems
KR920002165B1 (ko) * 1986-09-22 1992-03-19 에모리 유니버어시티 개선된 백신 및 제조방법
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5567859A (en) * 1991-03-19 1996-10-22 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US5674911A (en) * 1987-02-20 1997-10-07 Cytrx Corporation Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use
AU1396588A (en) * 1987-02-20 1988-09-14 Emory University Antiinfective compounds and method of use
EP0382736B1 (en) * 1987-07-27 1994-11-02 Commonwealth Scientific And Industrial Research Organisation Receptor membranes
US4853228A (en) * 1987-07-28 1989-08-01 Micro-Pak, Inc. Method of manufacturing unilamellar lipid vesicles
JP2517760B2 (ja) * 1989-05-11 1996-07-24 新技術事業団 水溶性高分子化医薬製剤
WO1991016058A1 (en) * 1990-04-26 1991-10-31 Cytrx Corporation Composition and method for topical treatment of damaged or diseased tissue
NZ238731A (en) * 1990-06-27 1996-02-27 Univ Emory Vaccine adjuvant compositions comprising ethyleneoxy-propyleneoxy-ethyleneoxy block copolymer or a non-toxic lipopolysaccharide
CA2106474C (en) * 1991-03-19 2004-02-10 R. Martin Emanuele Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US5696298A (en) * 1991-03-19 1997-12-09 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US5622649A (en) * 1991-06-27 1997-04-22 Emory University Multiple emulsions and methods of preparation
CA2120359C (en) * 1991-10-04 2000-12-26 Tomas Landh Particles, method of preparing said particles and uses thereof
US5681812A (en) * 1991-12-10 1997-10-28 Rush Presbyterian-St. Luke's Medical Center Methods and compositions for reducing multidrug resistance
US5470568A (en) * 1992-02-13 1995-11-28 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for cell repair
US5573934A (en) * 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
KR940003548U (ko) * 1992-08-14 1994-02-21 김형술 세탁물 건조기
JPH08506319A (ja) * 1992-10-08 1996-07-09 ヴァレリ ユ． アラホフ ミセル中に組み込まれた抗−新生物性組成物
US6153193A (en) * 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
US6277410B1 (en) * 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
US5840319A (en) * 1992-10-08 1998-11-24 Alakhov; Valery Yu Biological agent compositions
US5488034A (en) * 1993-02-02 1996-01-30 Xoma Corporation Pharmaceutical composition comprising BPI proteins
IL106578A (en) * 1993-08-03 2000-08-13 Yissum Res Dev Co Pharmaceutical compositions for drug targeting
JP3682475B2 (ja) * 1993-08-31 2005-08-10 靖久 桜井 水溶性抗癌剤
US5417982A (en) * 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
US5401296A (en) * 1994-06-28 1995-03-28 Martenson; Irvin Precious metal extraction process
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US6040295A (en) * 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy

Also Published As

Publication number Publication date
WO1996040056A1 (en) 1996-12-19
DE69615561D1 (de) 2001-10-31
PT839026E (pt) 2002-01-30
DE69615561T2 (de) 2002-07-11
EP0839026A1 (en) 1998-05-06
EP0839026B1 (en) 2001-09-26
US6153193A (en) 2000-11-28
ATE206041T1 (de) 2001-10-15
CA2236946A1 (en) 1996-12-19
AU6628496A (en) 1996-12-30
DK0839026T3 (da) 2002-01-21
JPH11507028A (ja) 1999-06-22

Similar Documents

Publication Publication Date Title
ES2163034T3 (es) Composiciones micelares de copolimeros de bloque de polieter, para la objetivizacion de agentes biologicos como diana.
ES2173876T3 (es) Nuevas 7-(sustituido)-8-(sustituido)-9-(amino sustituido)-6-desmetil-desoxitetraciclinas como agentes antibioticos.
BR0111222A (pt) Derivados fosfonados de glicopeptìdeo
ES2157994T3 (es) Inhibidores tetra y pentapeptidos sustituidos de la proteina farnesiltransferasa.
PT983087E (pt) Composicao de vacina multivalente com veiculo misto
ES2146782T3 (es) 6-aril-pirido(2,3-d)pirimidinas y naftiridinas para la inhibicion de la proliferacion celular inducida por la proteina tirosina quinasa.
ATE186736T1 (de) Aza-zyklohexapeptide
FR11C0037I2 (fr) Antibiotiques macrolides et traitement de la pasteurellose
ES2131496T3 (es) Mejoras relativas a derivados glicopeptidicos.
MX9800625A (es) Marcfortinas y paraherquamidas antiparasitarias.
AR010062A1 (es) Nuevos benzamidaldehidos y su utilizacion
ES2190246T3 (es) Nuevos compuestos de tiazolopirimidina.
AR016981A2 (es) Polipeptidos sinteticos
PT925789E (pt) Es oculares utilizacao de azitromicina no tratamento topico de infecco
ATE128714T1 (de) Erythromycinderivate.
AR002272A1 (es) Uso de amidas de fenilciclohexilcarboxilicos
ES2057341T3 (es) Ciclohexenos substituidos como agentes para el sistema nervioso central.
DE69936052D1 (de) N1 modifizierte glycopeptide
ATE66610T1 (de) Primycin enthaltendes kolloidales grundgel, verfahren zu dessen herstellung, dieses grundgel enthaltende pharmazeutische und pharmako- kosmetische kompositionen.
ES2102295B1 (es) Nuevos compuestos derivados de la n-benzoilmetil-piperidina.
DE69617956D1 (de) Zusammensetzungen, welche adp-ribosyltransferase-aktivität aufweisen und methoden für ihre herstellung und die verwendung derselben
ES2082559T3 (es) Nuevas composiciones de agentes frigorificos.
ES2059791T3 (es) Antibiotico a80915 y procedimiento para su produccion.
ES2122912A1 (es) Inhibidores de metalocarboxipeptidasas y moleculas derivadas como agentes antitumorales.
MX9302324A (es) Antagonistas de endotelina ii.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 839026

Country of ref document: ES